This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe

ONLINE REGISTRATION CLOSES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
2023 Information Coming Soon!
Menu
keyboard_arrow_right

Main Conference Day 2 - CET/CEST (Cent Europe Summer, GMT+2)

keyboard_arrow_leftSearch & Filter
search

Main Conference Day 2 - CET/CEST (Cent Europe Summer, GMT+2)

search
07:15 - 07:4025 mins
Registration, Coffee and Exhibit/Poster Viewing
    07:40 - 08:1030 mins
    MORNING SCIENTIFIC BRIEFING: Manufacturing Next-Generation Multi Domain Protein Pharmaceuticals Using the Leap-In Transposase® Platform
    • Claes Gustafsson, PhD - Co-Founder & CCO, ATUM
    08:15 - 08:205 mins
    Beyond Antibodies: New Developments for Therapy, Diagnostics and Research
    Chairman’s Remarks
    • Andreas Plückthun, PhD - Professor and Director, University of Zurich
    08:15 - 08:205 mins
    Strategies for Improving the Therapeutic Window of Antibody Drugs
    Chairwoman’s Remarks
    • Kerry Chester, PhD - Professor of Molecular Medicine, UCL Cancer Institute
    08:20 - 08:5030 mins
    Beyond Antibodies: New Developments for Therapy, Diagnostics and Research
    Modular Binding of Linear Epitopes
    • Andreas Plückthun, PhD - Professor and Director, University of Zurich
    08:20 - 08:5030 mins
    Strategies for Improving the Therapeutic Window of Antibody Drugs
    OPS-γδ: Opsonin Delivery from an Allogeneic Cell Therapy Platform
    • Jonathan Fisher, Ph.D. - NIHR Clinical Lecturer & GOSHC Springboard Fellow, UCL-GOS Institute of Child Health
    08:50 - 09:2030 mins
    Beyond Antibodies: New Developments for Therapy, Diagnostics and Research
    Ensovibep, A SARS-CoV-2 Pan-variant Neutralizing DARPin Therapeutic
    • Daniel Steiner, Ph.D. - SVP, Oncology Research, Molecular Partners
    08:50 - 09:2030 mins
    Strategies for Improving the Therapeutic Window of Antibody Drugs
    XTENylated Protease Activated T Cell Engagers: XPATS - A Novel Format to Mitigate the On-target, Off-tumor Problem
    • Tracy Young, PhD - Director, Protein Engineering, Amunix Pharmaceuticals
    09:20 - 09:5030 mins
    Beyond Antibodies: New Developments for Therapy, Diagnostics and Research
    Ubiquibodies: The Next Generation of Targeted Protein Degraders
    • Matthew DeLisa, Ph.D. - William L. Lewis Professor of Engineering, Cornell University
    09:20 - 09:5030 mins
    Strategies for Improving the Therapeutic Window of Antibody Drugs
    New Developments with Conditionally Activated Tetravalent Bispecific Antibodies
    • Neil Brewis, Ph.D. - Chief Scientific Officer, F-star Therapeutics
    09:50 - 10:2030 mins
    Networking Refreshment Break and Exhibit/Poster Viewing
      Concurrent Streams
      10:20 - 10:5030 mins
      Beyond Antibodies: New Developments for Therapy, Diagnostics and Research
      Pushing the Envelope of Synthetic Binding Proteins with Monobodies
      • Shohei Koide, PhD - Professor of Biologics Design, Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine
      10:20 - 10:5030 mins
      Strategies for Improving the Therapeutic Window of Antibody Drugs
      Peripheral and Tumoral Immune Activity in the Expansion Part of the First-in-Human DuoBody®-PD-L1x4-1BB (GEN1046) Trial
      • Nora Pencheva, Ph.D. - Associate Director, Translational Medicine Lead, Genmab B.V.
      10:50 - 11:2030 mins
      Beyond Antibodies: New Developments for Therapy, Diagnostics and Research
      Radionuclide Molecular Targeting of Cancer Using Engineered Scaffold Proteins
      • Vladimir Tolmachev, Ph.D. - Professor, Department of Immunology, Genetics, Uppsala University
      10:50 - 11:2030 mins
      Strategies for Improving the Therapeutic Window of Antibody Drugs
      A Triple-targeting DARPin T-cell Engager Approach to Improve Safety and Efficacy for the Treatment of AML
      • Christian Reichen, Ph.D. - Associate Director Oncology Research, Molecular Partners AG
      11:20 - 11:5030 mins
      Beyond Antibodies: New Developments for Therapy, Diagnostics and Research
      Generation of Antibody-like Modulators of Ion Channels by Fusing Cysteine Rich Miniproteins into Peripheral CDR Loops
      • Aneesh Karatt-Vellatt, PhD - Chief Scientific Officer, Maxion Therapeutics
      11:20 - 11:5030 mins
      Strategies for Improving the Therapeutic Window of Antibody Drugs
      Bringing Amanitin to the Clinic - Engineering a Therapeutic Window into a Poison
      • George Badescu, PhD - Chief Business Officer, Heidelberg Pharma
      Scientific Briefings
      11:50 - 12:5060 mins
      Scientific Briefing 1
      Applications of the Retrogenix Cell Microarray Technology for IND-enabling Specificity Screening
      • Diogo Rodrigues Ferreirinha - European Senior Account Manager, Charles River Laboratories
      11:50 - 12:2030 mins
      Scientific Briefing 2
      Engineering Human Antibodies Discovered with AlivaMab Mouse into a Dual-Antagonist Bispecific Antibody Therapeutic
      • Jonah Rainey, PhD - VP of Antibody Engineering and Protein Science, AlivaMab Discovery Services
      12:20 - 12:5030 mins
      Scientific Briefing 2
      EVOiR&D: An Integrated Discovery and Development Platform to Deliver Best-in-class Biologics at Evotec
      • Thierry Wurch, PhD - Senior VP, Integrated Biologics Discovery, EVOTEC (France) SAS
      12:50 - 13:5060 mins
      Networking Luncheon and Exhibit/Poster Viewing
        Scientific Briefings
        13:50 - 14:2030 mins
        Scientific Briefing 1
        Accelerating High Throughput Antibody Purification Using Dual Flow Chromatography
        • Vincent Batori, PhD - Application Specialist Biomolecules Europe, Biotage AB
        13:50 - 14:2030 mins
        Scientific Briefing 2
        Tracking Antibody Enrichment in Display Libraries with the IGX Platform
        • Lorenzo Fanchi - Team Lead Product Management, ENPICOM
        14:20 - 14:255 mins
        Non-cancer Applications of Therapeutic Antibodies
        Chairman’s Remarks
        • Hans de Haard, PhD - Chief Scientific Officer, Argenx
        14:20 - 14:255 mins
        T-Cell Engagers and Beyond
        Chairwoman’s Remarks
        • Janine Schuurman, Ph.D. - Corporate VP Research and Innovation, Genmab
        14:25 - 14:5530 mins
        Non-cancer Applications of Therapeutic Antibodies
        A New Treatment Concept in Pemphigus Therapy: Long Term Response to Rituximab
        • Sebastien Calbo, PhD - Research Scientist, Normandie University Rouen
        14:25 - 14:5530 mins
        T-Cell Engagers and Beyond
        CD3-bispecific Antibody Therapy is Effective in Solid Tumors after Increased T cell Infiltration Induced by Vaccines
        • Jim Middelburg - .., Leiden University Medical Center
        14:55 - 15:2530 mins
        Non-cancer Applications of Therapeutic Antibodies
        Mastering Fibrosis Resolution and Tissue Regeneration by HGF-mimetic Antibodies
        • Paolo Michieli, PhD - Chief Scientific Officer, AgomAb Therapeutics
        14:55 - 15:2530 mins
        T-Cell Engagers and Beyond
        Engineered Immunocompetent Models of the Human Intestine: Applications in TCB Safety Profiling and Beyond
        • Nikolche Gjorevski - Principal Scientist and Lead, Roche
        15:25 - 15:5530 mins
        Non-cancer Applications of Therapeutic Antibodies
        Data from the ADAPT Phase 3 Study of Efgartigimod in Generalized Myasthenia Graves Patients
        • James Howard Jr., MD - Professor of Neurology, Medicine and Allied Health, UNC Chapel Hill
        15:25 - 15:5530 mins
        T-Cell Engagers and Beyond
        A Novel Multivalent T-cell Engaging Bispecific Antibody for Selective Killing of Solid Tumor Cells
        • Brian Avanzino, Ph.D. - Scientist III, Discovery, Amgen
        15:55 - 16:2530 mins
        Networking Refreshment Break and Exhibit/Poster Viewing
          16:25 - 16:5530 mins
          Non-cancer Applications of Therapeutic Antibodies
          Human Antibody Repertoires are Simple, Unique, and Dynamic
          • Albert Bondt, PhD - Senior Scientist, Utrecht University
          16:25 - 16:5530 mins
          T-Cell Engagers and Beyond
          Developing Protease-Activated T Cell Engager Prodrugs with Improved Spatial and Temporal Controls
          • Jack Lin, Ph.D. - Senior Director, New Technologies, Harpoon Therapeutics
          16:55 - 17:2530 mins
          Non-cancer Applications of Therapeutic Antibodies
          RNA-Engineered Cell Therapies for Autoimmune Disease
          • Michael Singer, MD, PhD - Co-Founder, CSO and Director, Cartesian Therapeutics
          16:55 - 17:2530 mins
          T-Cell Engagers and Beyond
          The Gammabody Platform: Novel Bispecific Gamma-delta T Cell Engagers for the Treatment of Prostate Cancer
          • Paul Parren, PhD - EVP, Head of R&D, Lava Therapeutics
          17:25 - 17:5530 mins
          Non-cancer Applications of Therapeutic Antibodies
          A Therapeutic Antibody to ApoC3 for Treatment of Hypertriglyceridemia
          • Daniel Rader, MD - Seymour Gray Professor of Molecular Medicine, Perelman School of Medicine, University of Pennsylvania
          17:25 - 17:5530 mins
          T-Cell Engagers and Beyond
          In Vitro and In Vivo Studies Establish DuoBody®-CD3xB7H4 As a Novel Drug Candidate for the Treatment of Solid Cancers
          • Louise Koopman, PhD - Scientific Project Lead, Translational Research, Genmab
          17:55 - 18:005 mins
          Close of Conference
            Main Conference Day 1
            Filter
            Streams
            Formats
            Choose Day